Tuesday, July 31, 2012
Tonix Pharmaceuticals Holding Corp., of New York, reported that data from a comparative pharmacokinetic (PK) and bioavailability trial supported the continued development of TNX-102 (cyclobenzaprine) 2.4 mg sublingual tablets for bedtime administration to improve core fibromyalgia symptoms.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.